Related to Agennix Contracts DSM for Commercial Supply of a Dendritic Cell Mediated Immunotherapy

• BioInvent Cans Contract Manufacturing Activities to Focus on Proprietary Drug Development
  
• ImmunoCellular Therapeutics Taps UPenn to Progress Mid-Stage Glioblastoma Candidate
  
• Plant-Based Protein Production System Developed
  
• SAFC to Invest $6.25M to Fortify Kansas Facility
  
• Virdante Taps ProBioGen for Cell-Line Development
  
• Tarceva Gains EC Clearance as Maintenance Therapy in NSCLC
  
• Critical Biologics to Use Scarab’s Clean Genome E. coli for Production of Phase II Gelsolin Replacement Therapy
  
• CRO Aragen Negotiates Licenses to Cevec’s Human Amniotic Cell Line Expression System
  
• Glycos Biotechnologies to Build Biochemical Plant and R&D Facility in Malaysia
  
• OSI Accepts Astellas' Increased $4B Cash Takeover Offer
  
• Biotage Picks Up Caliper Sample-Prep Assets for $16.5M
  
• International Stem Cell and The Automation Partnership Ally to Enhance Cornea Tissue Production
  
• Clovis Signs On to Advance Avila’s Preclinical EGFR Mutant-Selective Inhibitor Program
  
• Abraxis Reports Phase III Success with Abraxane in First-Line NSCLC
  
• Cellectis to Apply Its Meganuclease Technology to Engineer Lonza Cell Line
  
• FDA Partially Lifts Clinical Hold on Merck Serono’s Anticancer Vaccine
  
• Esperion Taps TransGenRx for Protein Production to Support HDL-Related Research
  
• GSK and EDB Pledge $35M to Augment Green Manufacturing in Singapore
  
• Lonza to Manufacture HGS and GSK’s Lupus Drug Benlysta
  
• Cell Therapeutics Signs Manufacturing Deal for Pixantrone with NerPharMa